Genelux Q2 FY26 net loss widens to $9.47 million; revenue flat at no revenue

Reuters2026/08/13 17:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Genelux posted a net loss of $9.47 million in the quarter ended June 30, 2026, widening from $7.46 million a year earlier.
Research and development expense rose 36.78% to $6.51 million, driven by higher clinical and regulatory costs tied to the Phase 3 On Prime/GOG-3076 trial.
General and administrative costs edged up 3.39% to $3.14 million, on higher stock-based compensation partly offset by lower professional services.
Revenue was unchanged, with no revenue recognized in the first half; net loss widened to $18.4 million from $14.95 million.
Cash, cash equivalents, restricted cash and marketable securities totaled $18.7 million at June 30, 2026, expected to last into first-quarter 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037667), on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Genelux Q2 FY26 net loss widens to $9.47 million; revenue flat at no revenue

You may also like

Crypto prices